Sanofi has recorded encouraging results for its next-generation vaccine candidate used as a booster dose against Covid-19, during two clinical trials on this serum which it is developing jointly with the British GSK, he announced on Monday.
The French laboratory, which has still not marketed a vaccine against Covid-19, is continuing its trials on humans, including as a booster dose, while a majority of the population of Western countries has already received a primary -vaccination.
In this context, data from a phase III study (the last before marketing) on the new generation booster vaccine candidate from Sanofi and GSK induced a "significant increase" in the concentrations of neutralizing antibodies, compared to the concentrations preceding the administration of the booster dose, specifies Sanofi in its press release.
This increase in the immune defense was confirmed “against multiple variants of concern” in adults who had been vaccinated with messenger RNA vaccines, the vaccines developed by Pfizer/BioNTech and Moderna.
Preliminary data show a 40-fold increase in neutralizing antibody concentrations against the Omicron variant BA.1 subline.
In addition, Sanofi points out, the next-generation booster vaccine candidate has doubled the number of neutralizing antibodies against Omicron's BA.1 and BA.2 sublines, compared to the booster vaccine based on the original strain of the virus. .
"Stronger immune response", according to a study by the AP-HP
At the same time, an independent study conducted by the Assistance Publique - Hôpitaux de Paris (AP-HP) demonstrated that after a primary vaccination with two doses of the Cominarty vaccine from Pfizer-BioNTech, the candidate booster vaccine from Sanofi -GSK elicited a stronger immune response (measured by the concentrations of neutralizing antibodies generated) than the Pfizer-BioNTech booster vaccine or the first-generation Sanofi-GSK booster vaccine, targeting the original virus strain, did assert the French group.
Sanofi and GSK have developed this new booster vaccine candidate in parallel with the regulatory reviews currently undergoing their first-generation vaccine candidate.
He intends to submit all the data on this new serum in the coming weeks, in order to make it available later this year.
Sanofi is developing a recombinant protein vaccine, which uses the spike protein of the virus as an antigen to help the body recognize it.